Author Archives: Natalie Themm
Canary Speech Launches Canary Ambient™ Continuous Monitoring to Address Workplace Violence in Healthcare
AI-powered voice analysis expands to detect verbal aggression and prevent nurse burnout through real-time vocal biomarker technology, enhancing clinician safety and patient care
Owlet™ Secures CDSCO Approval for Dream Sock® and Plans 2026 Expansion into India
Owlet expands its global footprint, entering one of the world’s most promising digital health markets, with CDSCO-approved technology.
NUSANO AND ARICEUM THERAPEUTICS ANNOUNCE MULTI-ISOTOPE SUPPLY AGREEMENT
AGREEMENT INCLUDES ACTINIUM-225 (AC-225) AND LUTETIUM-177 (LU-177) TO SUPPORT ARICEUM’S THERAPEUTIC PROGRAMS
CancerVax Precision Therapy Successfully Avoids Healthy Liver Cells
In-vitro studies confirm that the Company’s novel Smart mRNA could drastically reduce off-target liver toxicity, a major issue affecting many cancer drugs
Halia Therapeutics Expands to Abu Dhabi
Halia Therapeutics Expands to Abu Dhabi
Leash Bio Announces Multi-Target Agreement with Monte Rosa Therapeutics
Leash Bio Announces Multi-Target Agreement with Monte Rosa Therapeutics
Merit Medical Announces SCOUT Milestone: 750,000 Patients Treated with Wire-Free Technology
SCOUT Radar Localization use grows, supporting more successful surgeries and improved patient care.
PhotoPharmics to Feature Photo Neurostimulation at the 2025 Movement Disorders Society International Congress
Attendees invited to Booth #732 for pivotal trial updates and to discuss unmet needs in Parkinson’s care.
Halia Therapeutics Named as 2025 Top 10 Longevity Breakthrough Award Winner
Halia Therapeutics Named as 2025 Top 10 Longevity Breakthrough Award Winner
Seek Labs Advances Development of Pan-Orthopoxvirus Therapeutic with BioSeeker™ and PTAP™
BioSeeker mapped more than 10,000 isolates and identified targetable regions that provide 100% strain coverage across the viral family.
Biolexis Therapeutics Initiates First-in-Human Clinical Trials for Novel, Oral Muscle-Sparing, Weight Loss and Type 2 Diabetes Therapies
Biolexis Therapeutics Initiates First-in-Human Clinical Trials for Novel, Oral Muscle-Sparing, Weight Loss and Type 2 Diabetes Therapies
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
